Can Afamelanotide and Plecanatide be used together?

There are no contraindications between the two compounds, and they work on entirely separate systems. However, there is no clinical evidence or medical rationale to combine them. If you have both EPP and constipation, your doctor would likely prescribe each independently based on your needs—not as a combination therapy.

Which peptide has more clinical evidence?

Afamelanotide has 23 clinical trials versus Plecanatide's 14, giving it a slightly larger evidence base. Both have A-grade evidence and FDA approval. The difference in trial count reflects their different development timelines and approval pathways, not necessarily a meaningful difference in safety or efficacy for their respective indications.

Why is Plecanatide approved in Canada but Afamelanotide isn't?

Regulatory pathways differ by country. Plecanatide was submitted to Health Canada for CIC/IBS-C and approved. Afamelanotide was not submitted to or approved by Health Canada, likely because EPP is so rare in Canada that commercial interest was limited. Geographic availability reflects manufacturer decisions and regional regulatory submissions.

Are these peptides available over the counter?

No. Both Afamelanotide and Plecanatide are prescription-only, FDA-approved (or EMA/Health Canada-approved) medications. They must be prescribed by a licensed healthcare provider and are not available without a doctor's order.

Which peptide works faster?

Plecanatide works within hours to days, as it directly affects intestinal fluid secretion. Afamelanotide takes weeks to months to build meaningful melanin protection, as it relies on gradual skin darkening through repeated stimulation. They operate on very different timescales because of their mechanisms.

Afamelanotide vs Plecanatide: Key Differences

Afamelanotide and Plecanatide are both FDA-approved peptides, but they work in entirely different ways and treat different conditions. Afamelanotide is a melanocortin receptor agonist designed to protect skin from UV damage in patients with a rare photosensitivity disorder. Plecanatide is a guanylate cyclase-C agonist that increases intestinal fluid secretion to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. While both are peptides approved by major regulatory bodies, they have different mechanisms, clinical evidence bases, target populations, and geographic availability. This guide breaks down what you need to know to understand how they differ.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide and melanocortin-1 receptor (MC1R) agonist developed to address a rare genetic condition. It's designed to stimulate melanin production in the skin, increasing photoprotection (the skin's natural defense against UV radiation).

The compound was developed specifically for erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder where patients experience severe pain and blistering when exposed to sunlight. Afamelanotide works by activating melanocytes—the cells responsible for producing melanin—helping the skin darken and provide natural UV protection.

Regulatory Status:

FDA-approved in the US (2014)
EMA-authorised in the EU
Not approved by Health Canada

The FDA approval was based on solid clinical data, with 23 documented clinical trials investigating its safety and efficacy.

What Is Plecanatide?

Plecanatide is a peptide agonist that targets the guanylate cyclase-C (GC-C) receptor in the intestines. Rather than working on the skin, it operates in the gastrointestinal system to increase intestinal fluid secretion and promote bowel movements.

The compound was developed to treat two common gastrointestinal conditions:

Chronic idiopathic constipation (CIC): long-term constipation without an identifiable underlying cause
Irritable bowel syndrome with constipation (IBS-C): a functional GI disorder characterized by constipation and abdominal discomfort

Research demonstrates that plecanatide stimulates intestinal fluid secretion and accelerates transit time, effectively addressing the primary symptoms of these conditions.

Regulatory Status:

FDA-approved in the US (2018)
Health Canada–approved
Not authorised by the EMA

Plecanatide has been evaluated in 14 clinical trials, establishing a robust evidence base.

Key Mechanism Differences

Understanding how these peptides work is essential to appreciating why they're not interchangeable:

Afamelanotide: Melanin-Focused

Afamelanotide binds to melanocortin-1 receptors on melanocytes, triggering a signaling cascade that increases melanin synthesis and skin darkening. This process takes time—typically several weeks of exposure and stimulation for noticeable darkening. The goal is photoprotection through the body's natural pigmentation response.

Plecanatide: Intestinal Fluid-Focused

Plecanatide activates guanylate cyclase-C receptors in the intestinal epithelium, leading to increased production of cyclic guanosine monophosphate (cGMP), which opens chloride channels and allows fluid to enter the intestinal lumen. This creates a osmotic effect that softens stool and stimulates bowel movements, often within hours.

Bottom line: One enhances skin pigmentation for UV protection; the other promotes bowel movement through fluid secretion. They have completely different targets and mechanisms.

Clinical Evidence

Afamelanotide Evidence

Afamelanotide has been studied across 23 clinical trials, predominantly in patients with erythropoietic protoporphyria. Key studies show that regular afamelanotide treatment combined with sun exposure significantly reduces phototoxic reactions, with improvements in quality of life, outdoor activity tolerance, and pain reduction.

The evidence is highly specific to EPP. There is limited evidence for other photosensitive conditions, and no evidence supporting use in healthy individuals for cosmetic skin darkening.

Plecanatide Evidence

Plecanatide has been evaluated in 14 clinical trials for CIC and IBS-C. Research shows efficacy in increasing weekly spontaneous bowel movements and improving constipation-related symptoms. Studies have demonstrated both safety and tolerability over extended treatment periods.

The clinical evidence for plecanatide is strong in both target populations, with consistent improvements across primary and secondary endpoints in multiple randomized controlled trials.

Regulatory Landscape

| Factor | Afamelanotide | Plecanatide | |--------|---------------|-------------| | FDA (US) | Approved | Approved | | EMA (EU) | Authorised | Not authorised | | Health Canada | Not approved | Approved | | Clinical Trials | 23 | 14 | | Evidence Grade | A | A |

Geographic availability differs meaningfully. If you're in the EU, afamelanotide is accessible through EMA authorisation but plecanatide is not. In Canada, the reverse is true.

Who Each Compound Suits

Afamelanotide Is Best For:

Patients with erythropoietic protoporphyria (EPP) who experience severe photosensitivity
Individuals in the US or EU seeking a photoprotective option approved for rare photosensitive disorders
People willing to undergo a multi-week treatment cycle to build melanin protection
Those seeking a non-pharmacological alternative to strict sun avoidance

Afamelanotide is not a general-population UV protection product and has no evidence supporting use in healthy individuals.

Plecanatide Is Best For:

Patients with chronic idiopathic constipation who haven't responded adequately to lifestyle changes or first-line treatments
Individuals with IBS-C experiencing frequent constipation and abdominal discomfort
People in the US or Canada seeking an FDA/Health Canada-approved GI peptide
Those who need symptom relief within hours or days rather than weeks

Plecanatide is not appropriate for acute constipation and works best as part of a sustained treatment regimen.

Side Effect Profiles

Afamelanotide

Common side effects include nausea, facial flushing, and injection site reactions. Because it stimulates melanin production, there is a theoretical risk of increased mole count or changes to existing moles, requiring regular dermatological monitoring in some cases.

Plecanatide

The most common side effect is diarrhea, which occurs in a significant proportion of users. Other reported effects include abdominal pain and nausea. Diarrhea is generally dose-related and can be managed through dosage adjustment or discontinuation.

Bottom Line: Are They Competitors?

No. These are not competing therapies—they address entirely different medical needs in different organ systems. Comparing them is a bit like comparing insulin to antibiotics: both are valuable peptide-based therapeutics, but they treat different diseases.

Choosing between them depends on what condition you or a healthcare provider is trying to address. If it's photosensitivity, afamelanotide is the peptide option. If it's constipation, plecanatide is the peptide option. They don't overlap.

Related Peptides

If you're exploring peptide therapeutics, you might also consider:

Octreotide, a somatostatin analog used in endocrine disorders
Leuprolide, a GnRH agonist for hormone-sensitive cancers
Exenatide, a GLP-1 receptor agonist for type 2 diabetes

For more on how peptides work, see our guides to receptor agonists and bioavailability.

Afamelanotide vs Plecanatide: A Clear Comparison